Our results identify an enhanced premetastatic hepatic immune microenvironment which might promote initial tumor cell rejection and consequently decreased hepatic melanoma colonization, as initial tumor cell retention in mice with Lyve-1 deficiency was unaltered. This evidence concerns the gene LYVE1 and melanoma.